Iron Deficiency Anemia Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others), By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Iron Deficiency Anemia Market, comprising therapeutic solutions like oral and parenteral iron formulations aimed at replenishing iron stores and normalizing hemoglobin levels, is projected to grow from USD 5.89 Billion in 2025 to USD 9.18 Billion by 2031, exhibiting a 7.68% CAGR. This growth is primarily driven by the escalating burden of chronic diseases and maternal health conditions necessitating consistent hematological intervention, alongside increasing awareness of nutritional deficits, with updated 2025 estimates indicating that 30.7% of women aged 15-49 years were affected by anemia globally.
Market Driver
The increasing burden of Chronic Kidney Disease (CKD) and gastrointestinal disorders serves as a primary catalyst for market expansion, as these conditions frequently disrupt iron absorption and utilization, necessitating consistent iron supplementation for patients, exemplified by Akebia Therapeutics' Auryxia generating $152.2 million in net product revenues for full year 2024 in the renal care space. Concurrently, a heightened focus on maternal health and the management of pregnancy-related anemia significantly propels therapeutic adoption, with governmental and health organization mandates increasingly prioritizing screening and treatment; the World Health Organization reported that 35.5% of pregnant women aged 15-49 years worldwide were affected by anemia in 2023, which has spurred the uptake of novel oral formulations like Accrufer, reporting 153% year-over-year revenue growth to $29.3 million in 2024 for Shield Therapeutics.
Market Challenge
The adverse event profiles associated with standard iron replacement therapies present a direct and significant impediment to the Global Iron Deficiency Anemia Market's expansion. Oral iron formulations frequently induce severe gastrointestinal distress, leading to patient non-compliance and premature discontinuation, while intravenous administration carries risks of hypersensitivity reactions and necessitates clinical supervision, creating logistical obstacles that limit product uptake, especially in resource-constrained settings. These safety and tolerability issues prevent the market from fully capitalizing on the urgent therapeutic needs of high-risk demographics, such as the 35.5% of pregnant women aged 15-49 years globally affected by anemia, thereby restricting widespread adoption of effective iron therapies and hampering overall market revenue potential.
Market Trends
The market is witnessing an accelerated adoption of high-dose intravenous iron therapies, driven by the clinical need to streamline treatment protocols and minimize hospital visits by enabling complete iron repletion in a single administration, which significantly enhances outpatient efficiency, as reflected in Pharmacosmos' annual revenue surpassing DKK 3 billion, attributed to the global uptake of its high-dose monoferric formulation. Simultaneously, the competitive landscape is being reshaped by the market entry and expansion of biosimilar iron therapeutics, triggered by the expiration of patents for established branded intravenous treatments, which provides cost-effective options for healthcare systems and compels incumbents to adapt strategies, with CSL Limited reporting $527 million in iron product sales for the period, achieving volume growth despite intensifying generic competition.
Key Market Players
* AbbVie Inc.
* Pfizer Inc.
* Takeda Pharmaceutical Company Limited
* Novartis AG
* Amgen Inc.
* Bayer AG
* Fresenius Kabi AG
* Vifor Pharma Group
* Glenmark Pharmaceuticals Ltd.
* Dr. Reddy's Laboratories Ltd.
Report Scope
In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Iron Deficiency Anemia Market, By Therapy Type
* Oral Iron Therapy
* Parenteral Iron Therapy
* Red Blood Cell Transfusion
* Others
# Iron Deficiency Anemia Market, By Therapy Areas
* Obstetrics and Gynecology
* Oncology
* Congestive Heart Failure (CHF)
* Inflammatory Bowel Disease
* Renal
* Others
# Iron Deficiency Anemia Market, By End User
* Hospitals & Clinics
* Ambulatory Care Centers
* Others
# Iron Deficiency Anemia Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.
Available Customizations:
Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Iron Deficiency Anemia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
5.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Iron Deficiency Anemia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy Type
6.2.2. By Therapy Areas
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Iron Deficiency Anemia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy Type
6.3.1.2.2. By Therapy Areas
6.3.1.2.3. By End User
6.3.2. Canada Iron Deficiency Anemia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy Type
6.3.2.2.2. By Therapy Areas
6.3.2.2.3. By End User
6.3.3. Mexico Iron Deficiency Anemia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy Type
6.3.3.2.2. By Therapy Areas
6.3.3.2.3. By End User
7. Europe Iron Deficiency Anemia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Therapy Areas
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Iron Deficiency Anemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy Type
7.3.1.2.2. By Therapy Areas
7.3.1.2.3. By End User
7.3.2. France Iron Deficiency Anemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy Type
7.3.2.2.2. By Therapy Areas
7.3.2.2.3. By End User
7.3.3. United Kingdom Iron Deficiency Anemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy Type
7.3.3.2.2. By Therapy Areas
7.3.3.2.3. By End User
7.3.4. Italy Iron Deficiency Anemia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy Type
7.3.4.2.2. By Therapy Areas
7.3.4.2.3. By End User
7.3.5. Spain Iron Deficiency Anemia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy Type
7.3.5.2.2. By Therapy Areas
7.3.5.2.3. By End User
8. Asia Pacific Iron Deficiency Anemia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Therapy Areas
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Iron Deficiency Anemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy Type
8.3.1.2.2. By Therapy Areas
8.3.1.2.3. By End User
8.3.2. India Iron Deficiency Anemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy Type
8.3.2.2.2. By Therapy Areas
8.3.2.2.3. By End User
8.3.3. Japan Iron Deficiency Anemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy Type
8.3.3.2.2. By Therapy Areas
8.3.3.2.3. By End User
8.3.4. South Korea Iron Deficiency Anemia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy Type
8.3.4.2.2. By Therapy Areas
8.3.4.2.3. By End User
8.3.5. Australia Iron Deficiency Anemia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy Type
8.3.5.2.2. By Therapy Areas
8.3.5.2.3. By End User
9. Middle East & Africa Iron Deficiency Anemia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Therapy Areas
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Iron Deficiency Anemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy Type
9.3.1.2.2. By Therapy Areas
9.3.1.2.3. By End User
9.3.2. UAE Iron Deficiency Anemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy Type
9.3.2.2.2. By Therapy Areas
9.3.2.2.3. By End User
9.3.3. South Africa Iron Deficiency Anemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy Type
9.3.3.2.2. By Therapy Areas
9.3.3.2.3. By End User
10. South America Iron Deficiency Anemia Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy Type
10.2.2. By Therapy Areas
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Iron Deficiency Anemia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy Type
10.3.1.2.2. By Therapy Areas
10.3.1.2.3. By End User
10.3.2. Colombia Iron Deficiency Anemia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy Type
10.3.2.2.2. By Therapy Areas
10.3.2.2.3. By End User
10.3.3. Argentina Iron Deficiency Anemia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy Type
10.3.3.2.2. By Therapy Areas
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Iron Deficiency Anemia Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Takeda Pharmaceutical Company Limited
15.4. Novartis AG
15.5. Amgen Inc.
15.6. Bayer AG
15.7. Fresenius Kabi AG
15.8. Vifor Pharma Group
15.9. Glenmark Pharmaceuticals Ltd.
15.10. Dr. Reddy's Laboratories Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們